Instructions For Use. in the United States and Outside the United States. The information can be viewed online, downloaded or printed. The information on this page is intended for healthcare professionals. Patient-specific information is available in the "Patients" section of this site. Patients should consult a healthcare professional ...
Show more
See More
This User Manual includes Safety information, Dressing Applications and Clinical Guidelines for veterinary use. These guidelines are only general recommendations. Consult treating veterinarian as individual patient circumstances may vary.
Show more
See More
here to support you. Call Acelity at 800-275-4524 with questions or to speak to a clinician trained on your PREVENA™ System. Or visit prevena4patients.com for a copy of the PREVENA™ Therapy Patient Guide. It is important that you discuss the potential benefits and risks of any specific therapy with your doctor to decide whether it is right ...
Show more
See More
Acelity L.P. Inc., was a privately held medical device company. It was a non-operating holding company who wholly owned subsidiaries developed advanced wound therapeutics products. The advanced wound therapeutics business was conducted by Kinetic Concepts, Inc. (KCI) and its subsidiaries, including Systagenix.. The company reported $1.87 billion in annual revenue globally in 2015.
Show more
See More
Patient-specific information is available in the "Patients" section of this site. Patients should consult a healthcare professional regarding specific medical conditions and treatments. The information on this page is intended for healthcare professionals.
Acelity. Acelity L.P. Inc., is a privately held medical device company. It is a non-operating holding company whose wholly owned subsidiaries develop advanced wound therapeutics products. The advanced wound therapeutics business is conducted by Kinetic Concepts, Inc. (KCI) and its subsidiaries, including Systagenix.
That same year, Acelity acquired exclusive worldwide rights from the GID Group, Inc. to develop, manufacture and commercialize the REVOLVE System, a fat processing technology used in both reconstructive and cosmetic procedures to facilitate high-volume, autologous fat grafting.
2013: KCI acquired Systagenix Wound Management, formerly Johnson & Johnson's professional wound care business for $485 million. 2014: KCI's parent company announced that KCI, LifeCell and Systagenix would operate under one global medical technology brand known as Acelity.